RBM20
protein-codingRNA binding motif protein 20, the group of RNA binding motif containing
Gene summary
This gene encodes a protein that binds RNA and regulates splicing. Mutations in this gene have been associated with familial dilated cardiomyopathy. [provided by RefSeq, Apr 2014]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~195.1 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0005021
Submitter: ClinGen
RBM20 was first reported in relation to autosomal dominant dilated cardiomyopathy (DCM) in 2009 (Brauch et al, 2009, PMID: 19712804). To date, a large number of studies have reported over 25 RBM20 variants in DCM patients (Key papers include 26084686, Hey et al, 2019, PMID: 30871348; Li et al, 2010, PMID: 20590677; Millat et al, 2011, PMID: 21846512). Human evidence supporting this gene-disease relationship includes case-level data and segregation data, including 55 index cases with DCM carrying RBM20 variants. Brauch et al (2009, PMID: 19712804) performed linkage analysis on two large DCM families to identify RBM20 as the disease locus and subsequent screening of 8 DCM families identified a total of 5 RBM20 variants (p.Pro638Leu, p.Arg636His, p.Arg636Ser, p.Ser637Gly, p.Arg634Gln). In addition, this gene-disease association is supported by experimental evidence reported in several studies. In particular, Beqqali et al (2016, PMID: 27496873) performed functional studies on the p.E913K variant. They investigated human cardiac tissue with p.E913K and U-2 OS transfected cells and observed down-regulation of the RBM20 protein by Western blot. They also showed by RNA-seq analysis that p.E913K affects titin splicing. In RBM20 deficient rats, the observed phenotype resembled human DCM with arrhythmia and sudden cardiac death (Guo et al, 2012, PMID: 22466703). The same study also identified the p.S635A variant which in splice reporter assays rendered RBM20 inactive. Human induced pluripotent stem cells (iPSC) carrying the p.S636A variant showed abnormal distribution of alpha-actinin and defective calcium handling (Streckfuss-Bömekeet al, 2017, PMID: 28941705). Gene expression analysis in iPSCs carrying the p.S636A variant showed dysregulated sarcomeric (TTN and LDB3) and calcium handling (CAMK2D and CACNA1C) genes (Oishi et al, 2016, PMID: 26604126). In summary, there is strong evidence to support the relationship between RBM20 and autosomal dominant DCM. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. Therefore, the classification has been revised to definitive. This classification was approved by the ClinGen Dilated Cardiomyopathy Working Group on October 11, 2019 (SOP Version 7).
Inheritance Pattern: AD
Disease ID:MONDO:0013168
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0015470
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0013168
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0024573
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0013168
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0013168
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0005045
Submitter: ClinGen
RBM20 was first reported in relation to autosomal dominant HCM in 2021 (Dai et al. PMID: 34333030). At least 13 variants (e.g. missense, splice acceptor, frameshift) have been reported in humans. Evidence supporting this gene-disease relationship includes only case-level data. Variants in this gene have been reported in at least 13 probands in 1 publication (PMID: 34333030). Additionally, there are families described in the literature with no segregation of RBM20 variants with HCM phenotype; these publications were not scored. There are no publications showing a clear segregation of RBM20 variants with HCM in family members. The mechanism for disease is unknown. In summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel on October 26, 2023 (SOP Version 9).
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular
Intervention: Cardiovascular
Rationale: Surveillance (eg, with echocardiography and electrocardiography), preventive measures and medical management may help decrease morbidity; Cardiac transplantation has been described
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to RBM20 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001134363.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 10 | 562 | 10 | 582 | ||
| missense | 4 | 22 | 919 | 318 | 9 | 1272 |
| nonsense | 29 | 18 | 11 | 58 | ||
| start loss | 0 | |||||
| frameshift | 39 | 30 | 21 | 1 | 91 | |
| splice donor/acceptor (+/-2bp) | 19 | 3 | 22 | |||
| Total | 72 | 89 | 964 | 881 | 19 | 2025 |
Highest pathogenic variant AF is 0.000032223637
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001127835.2 | 14 | MANE Select | |
| Ensembl | ENSP00000358532.3 | 14 | MANE Select | |
| Ensembl | ENSP00000520684.1 | 14 | Standard | |
| Ensembl | ENSP00000520684.1 | 14 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Biological Process
- mRNA processing
- heart development
- RNA splicing
- positive regulation of RNA splicing
Molecular Function
- RNA binding
- zinc ion binding
Cellular Component
- nucleus
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000369519
- Coding exons
- 14
- Length
- 195073
- Individuals with no LoFs
- 0
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 0
- Defined
- 0
- p
- 0.00
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.67 | 543 | 664 | 0.818 | 0.0000376 | 7995 |
| Missense (PolyPhen) | 184 | 246.54 | 0.74633 | 2879 | ||
| Synonymous | 2.10 | 226 | 270 | 0.837 | 0.0000165 | 2450 |
| Loss of Function | 5.22 | 7 | 44.6 | 0.157 | 0.00000218 | 575 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0 | 0.0 | absent |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: RNA-binding protein that acts as a regulator of mRNA splicing of a subset of genes involved in cardiac development. Regulates splicing of TTN (Titin). {ECO:0000269|PubMed:22466703}.;
Intolerance Scores
- RVIS EVS
- 1.02
- RVIS percentile EVS
- 90.98
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.140
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |